Cargando…
Major Histocompatibility Complex Class I Chain-Related α (MICA) STR Polymorphisms in COVID-19 Patients
The SARS-CoV-2 disease presents different phenotypes of severity. Comorbidities, age, and being overweight are well established risk factors for severe disease. However, innate immunity plays a key role in the early control of viral infections and may condition the gravity of COVID-19. Natural Kille...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266713/ https://www.ncbi.nlm.nih.gov/pubmed/35805975 http://dx.doi.org/10.3390/ijms23136979 |
_version_ | 1784743535619080192 |
---|---|
author | Gutiérrez-Bautista, Juan Francisco Martinez-Chamorro, Alba Rodriguez-Nicolas, Antonio Rosales-Castillo, Antonio Jiménez, Pilar Anderson, Per López-Ruz, Miguel Ángel López-Nevot, Miguel Ángel Ruiz-Cabello, Francisco |
author_facet | Gutiérrez-Bautista, Juan Francisco Martinez-Chamorro, Alba Rodriguez-Nicolas, Antonio Rosales-Castillo, Antonio Jiménez, Pilar Anderson, Per López-Ruz, Miguel Ángel López-Nevot, Miguel Ángel Ruiz-Cabello, Francisco |
author_sort | Gutiérrez-Bautista, Juan Francisco |
collection | PubMed |
description | The SARS-CoV-2 disease presents different phenotypes of severity. Comorbidities, age, and being overweight are well established risk factors for severe disease. However, innate immunity plays a key role in the early control of viral infections and may condition the gravity of COVID-19. Natural Killer (NK) cells are part of innate immunity and are important in the control of virus infection by killing infected cells and participating in the development of adaptive immunity. Therefore, we studied the short tandem repeat (STR) transmembrane polymorphisms of the major histocompatibility complex class I chain-related A (MICA), an NKG2D ligand that induces activation of NK cells, among other cells. We compared the alleles and genotypes of MICA in COVID-19 patients versus healthy controls and analyzed their relation to disease severity. Our results indicate that the MICA*A9 allele is related to infection as well as to symptomatic disease but not to severe disease. The MICA*A9 allele may be a risk factor for SARS-CoV-2 infection and symptomatic disease. |
format | Online Article Text |
id | pubmed-9266713 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92667132022-07-09 Major Histocompatibility Complex Class I Chain-Related α (MICA) STR Polymorphisms in COVID-19 Patients Gutiérrez-Bautista, Juan Francisco Martinez-Chamorro, Alba Rodriguez-Nicolas, Antonio Rosales-Castillo, Antonio Jiménez, Pilar Anderson, Per López-Ruz, Miguel Ángel López-Nevot, Miguel Ángel Ruiz-Cabello, Francisco Int J Mol Sci Article The SARS-CoV-2 disease presents different phenotypes of severity. Comorbidities, age, and being overweight are well established risk factors for severe disease. However, innate immunity plays a key role in the early control of viral infections and may condition the gravity of COVID-19. Natural Killer (NK) cells are part of innate immunity and are important in the control of virus infection by killing infected cells and participating in the development of adaptive immunity. Therefore, we studied the short tandem repeat (STR) transmembrane polymorphisms of the major histocompatibility complex class I chain-related A (MICA), an NKG2D ligand that induces activation of NK cells, among other cells. We compared the alleles and genotypes of MICA in COVID-19 patients versus healthy controls and analyzed their relation to disease severity. Our results indicate that the MICA*A9 allele is related to infection as well as to symptomatic disease but not to severe disease. The MICA*A9 allele may be a risk factor for SARS-CoV-2 infection and symptomatic disease. MDPI 2022-06-23 /pmc/articles/PMC9266713/ /pubmed/35805975 http://dx.doi.org/10.3390/ijms23136979 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gutiérrez-Bautista, Juan Francisco Martinez-Chamorro, Alba Rodriguez-Nicolas, Antonio Rosales-Castillo, Antonio Jiménez, Pilar Anderson, Per López-Ruz, Miguel Ángel López-Nevot, Miguel Ángel Ruiz-Cabello, Francisco Major Histocompatibility Complex Class I Chain-Related α (MICA) STR Polymorphisms in COVID-19 Patients |
title | Major Histocompatibility Complex Class I Chain-Related α (MICA) STR Polymorphisms in COVID-19 Patients |
title_full | Major Histocompatibility Complex Class I Chain-Related α (MICA) STR Polymorphisms in COVID-19 Patients |
title_fullStr | Major Histocompatibility Complex Class I Chain-Related α (MICA) STR Polymorphisms in COVID-19 Patients |
title_full_unstemmed | Major Histocompatibility Complex Class I Chain-Related α (MICA) STR Polymorphisms in COVID-19 Patients |
title_short | Major Histocompatibility Complex Class I Chain-Related α (MICA) STR Polymorphisms in COVID-19 Patients |
title_sort | major histocompatibility complex class i chain-related α (mica) str polymorphisms in covid-19 patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266713/ https://www.ncbi.nlm.nih.gov/pubmed/35805975 http://dx.doi.org/10.3390/ijms23136979 |
work_keys_str_mv | AT gutierrezbautistajuanfrancisco majorhistocompatibilitycomplexclassichainrelatedamicastrpolymorphismsincovid19patients AT martinezchamorroalba majorhistocompatibilitycomplexclassichainrelatedamicastrpolymorphismsincovid19patients AT rodrigueznicolasantonio majorhistocompatibilitycomplexclassichainrelatedamicastrpolymorphismsincovid19patients AT rosalescastilloantonio majorhistocompatibilitycomplexclassichainrelatedamicastrpolymorphismsincovid19patients AT jimenezpilar majorhistocompatibilitycomplexclassichainrelatedamicastrpolymorphismsincovid19patients AT andersonper majorhistocompatibilitycomplexclassichainrelatedamicastrpolymorphismsincovid19patients AT lopezruzmiguelangel majorhistocompatibilitycomplexclassichainrelatedamicastrpolymorphismsincovid19patients AT lopeznevotmiguelangel majorhistocompatibilitycomplexclassichainrelatedamicastrpolymorphismsincovid19patients AT ruizcabellofrancisco majorhistocompatibilitycomplexclassichainrelatedamicastrpolymorphismsincovid19patients |